Pacific Edge Limited has released a shareholder letter providing an update on recent developments and strategic directions. The letter emphasizes the company's focus on capital preservation as it aims to regain Medicare coverage. Details regarding a planned Share Purchase Plan (SPP) are included, which will be offered to eligible retail shareholders at the same price as a recent placement, expected to open in mid-July. The SPP and shareholder approval of the placement are essential for maintaining momentum and responding strategically to challenges and opportunities. The letter also highlights the inclusion of Cxbladder in the American Urological Association's guideline as a significant milestone. Shareholders are encouraged to review the SPP documentation and the Notice of Annual Shareholders' Meeting to be held in Auckland on 6 August 2025. The full letter can be accessed through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。